Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia

Blood

Volumn 118, Issue 18, 2011, Pages 4985-4991

  Ware, Russell E ^a   Despotovic, Jenny M ^a   Mortier, Nicole A ^a   Flanagan, Jonathan M ^a   He, Jin ^b   Smeltzer, Matthew P ^b   Kimble, Amy C ^b   Aygun, Banu ^b   Wu, Song ^b   Howard, Thad ^a   Sparreboom, Alex ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; HEMOGLOBIN F; HYDROXYUREA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80855133522     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-364190     Document Type: Article

References (40)

1. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009;62-69.
2. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010; 115(26):5300-5311.
3. Charache S, Dover GH, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992; 79(10):2555-2565.
4. Kinney TR, Helms RW, O'Branksi EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550-1554. (Pubitemid 29411304)
5. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045. (Pubitemid 38326218)
6. de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91(1):125-128. (Pubitemid 43235395)
7. Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2008;52(5):609-615.
8. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-1322.
9. Wang WC,Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anemia: a multicenter, randomized, control trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
10. Steinberg MH, McCarthy WF, Castro O, et al. Investigators of the multicenter study of hydroxyurea in sickle cell anemia and MSH patients'follow-up. Am J Hematol. 2010;85(6):403-408.
11. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: results of a 17-year, single center trial (LaSHS). Blood. 2010;115(12):2354-2363.
12. Lobo C, Hankins JS, Moura P, Pinto JC. Hydroxyurea therapy reduces mortality among children with sickle cell disease [abstract]. Blood. 2010;116(21):Abstract 843.
13. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008;55(2):483-501. (Pubitemid 351447270)
14. Yan JH, Ataga K, Kaul S, et al. The influence of renal function on hydroxyurea pharmacokinetics in adults in sickle cell disease. J Clin Pharmacol. 2005;45(4):434-445. (Pubitemid 40490416)
15. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386-394. (Pubitemid 350187450)
16. Fabricius E, Rajewsky F. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol. 1971;16(7):679-683.
17. Harrod VL, Howard T, Abboud MR, et al. Chemical and functional analysis of generic hydroxyurea formulations. Pediatr Hematol Oncol. 2008;25(5):423-429. (Pubitemid 351874098)
18. Walker AL, Franke RM, Sparreboom A, Ware RE. Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011;39(4):446-456.
19. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A. 2007;104(27):11346-11351. (Pubitemid 47175143)
20. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105(33):11869-11874.
21. Tibshirani R. Regression shrinkage and selection via the lasso. J Roy Statist Soc Serv B. 1996;58: 267-288.
22. Efron B, Hastie T, Johnstone T, Tibshirani R. Least angle regression. Ann Statist. 2004;32(2): 407-499. (Pubitemid 41250302)
23. Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood. 2008; 111(3):997-1003. (Pubitemid 351213376)
24. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005;79(2):107-113. (Pubitemid 40770668)
25. Lanzkron S, Haywood C Jr, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006; 81(12):927-932. (Pubitemid 44864450)
26. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7):2685-2690. (Pubitemid 40446257)
27. Hankins JS, Ware RE, Rogers ZR, et al. Longterm hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269-2275. (Pubitemid 41510795)
28. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-1047. (Pubitemid 47267446)
29. Flanagan JM, Howard TA, Mortier NA, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res. 2010;698(1-2):38-42.
30. McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011;154(1):134-140.
31. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Int Med. 2008; 148(12):932-938. (Pubitemid 351860825)
32. Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998;91(5): 1533-1541. (Pubitemid 28110316)
33. de Montalembert M, Bachir D, Hulin A, et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica. 2006;91(12):1685- 1688. (Pubitemid 46032966)
34. Aygun B, Mortier N, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfiltration and microalbuminuria in children with sickle cell anemia. Pediatr Nephrol. 2011;26(8):1285-1290.
35. Steinberg MH, Lu Z-H, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood. 1997;89(3): 1078-1088. (Pubitemid 27121303)
36. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10-14. (Pubitemid 34532957)
37. Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease: a study of clinic-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25-31.
38. Nolan VG, Ma Q, Cohen HT, et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. Am J Hematol. 2007; 82(3):179-184. (Pubitemid 46363782)
39. Juul T, Malolepszy A, Dybkaer K, et al. The in vivo toxicity of hydroxyurea depends on its direct target catalase. J Biol Chem. 2010;285(28):21411-21415.
40. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3): 158-165.